

ISO 18562-1:2017-03 (E)

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 1: Evaluation and testing within a risk management process

Contents	Page
Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 General principles applying to biocompatibility evaluation of medical devices	6
4.1 General	6
4.2 Type tests	7
4.3 Biocompatibility hazard identification	8
4.4 Extent of risk assessment	8
4.5 Biocompatibility evaluation plan	9
4.6 Selection of tests	10
4.7 Subsequent evaluation	10
5 Contamination of breathing gas from gas pathways	11
5.1 * Duration of use	11
5.2 Particulate matter (pm) emissions	13
5.3 Volatile organic compound (voc) emissions	13
5.4 Leachable substances in condensate	13
6 Adjustment for different patient groups	13
6.1 General considerations	13
6.2 Adjustment for body weight	13
6.3 * Deriving a permitted concentration from a tolerable exposure	14
7 * Deriving allowable limits	14
7.1 General process	14
7.2 For medical devices intended for limited exposure use (24 h)	15
7.3 For medical devices intended for prolonged exposure use (>24 h but <30 d)	16
7.4 For medical devices intended for permanent contact (30 d)	16
8 Risk benefit analysis	16
9 Assess the biocompatibility of the medical device	17
Annex A (informative) Rationale and guidance	18
Annex B (informative) Reference to the essential principles	20
Annex C (informative) Terminology--Alphabetized index of defined terms	21
Bibliography	23